Navigation Links
Osteotech's Plexur M(TM) Biocomposite Receives FDA Clearance in Spine
Date:7/29/2008

EATONTOWN, N.J., July 29 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic solutions for regenerative healing, announced today that the United States Food and Drug Administration ("FDA") has cleared its 510(k) submission for Plexur M(TM) Biocomposite for use in spinal applications. In spinal applications, Plexur M(TM) may be used in conjunction with autograft as a bone void filler. In March 2008, Osteotech received FDA clearance for Plexur M(TM) to be used in filling bony voids or gaps in the pelvis and extremities.

Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer, stated, "We are very pleased to receive FDA clearance for use of Plexur M(TM) in the spine. Plexur M(TM) is the second, of what we hope to be many more, bone-polymer biocomposites developed under our proprietary Plexur(R) Technology."

Mr. Owusu-Akyaw continued, "We are in the process of completing all of our internal activities for a limited launch of Plexur M(TM). By the end of the third quarter, we plan to introduce Plexur M(TM) to a small, select group of key surgeons who will utilize the product in a wide variety of orthopedic procedures, including spine, trauma and joints. We will utilize the knowledge gained from these surgeons to finalize our product uses, complete our technique guides and marketing materials and train our sales team."

The Plexur(R) Technology is designed to utilize bone tissue for procedure-specific surgical applications in combination with a wide variety of polymers. On a worldwide basis, Osteotech currently controls 33 patents and over 65 pending patent applications covering the Plexur(R) Technology for human and xenograft bone tissue.

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing OsteoBiologic solutions for regenerative medicine to support surgeons and their patients in the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function. For further information regarding Osteotech, this press release or the conference call, please go to Osteotech's website at http://www.osteotech.com.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements (as such are defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company's ability to develop and introduce new products, differences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and services, the impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. Certain of these factors are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. All information in this press release is as of July 29, 2008 and the Company does not intend to update this information.


'/>"/>
SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Osteotechs Plexur(R) Technology to Be Used in Craniofacial Reconstruction Program Funded by the Armed Forces Institute of Regenerative Medicine
2. Osteotechs Plexur P(TM) Receives FDA Clearance as Bone Void Filler and Bone Graft Extender in Spine
3. Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite
4. Simbionix Releases Powerful New Learning Management System With Enhanced True Assessment System(TM)
5. Studies Show USGI Medicals EndoSurgical Operating System(TM) Enables Incisionless Surgery to Reduce Gastric Pouch and Stoma After Gastric Bypass
6. EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board
7. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
8. EnzySurge, Maker of DermaStream(TM), Completes Funding Round of US$4 Million
9. More Than 700 Physicians and Administrators Participate in the Visian ICL Growth Program(TM) Launch
10. Elusys Anthim(TM) Dramatically Improves Survival of Animals Treated After Active Anthrax Infection
11. EnzySurge, Maker of DermaStream(TM), Establishes a US Office in the Virginia Biotech Commercialization Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... 29, 2017 , ... ComplianceOnline, the leading governance, risk and compliance advisory network ... Device Summit 2017 venue and speaker lineup. The Summit will take place on June ... The Omni Parker House Hotel, which is located at 60 School Street, Boston, MA ...
(Date:3/29/2017)... 2017  Halozyme Therapeutics, Inc. (NASDAQ: HALO), a ... today announced that an Oncologic Drug Advisory Committee ... 11 to 0 that the benefit/risk of rituximab/hyaluronidase ... for patients in the proposed indications of follicular ... leukemia. The FDA action date is June 26, ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... edge instrumentation for cell-based assays, disperses a quarterly travel award to noteworthy scientists ... Today the company announced that its new round of awards are being given ...
(Date:3/29/2017)... ... March 29, 2017 , ... Bactana Animal Health, a company developing natural products ... through enhancement of the gut microbiota, today announced the closing of its first round ... York-based Sustainable Income Capital Management, LLC and a number of private investors. The company ...
Breaking Biology Technology:
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , a ... globally, announces significant enhancements to new and core technologies ... New products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity ... technology provides the fastest and most accurate capture software ...
(Date:2/28/2017)... BARCELONA , Spanien, 27. Februar 2017 /PRNewswire/ ... durch Iris-Scan, wird seine erstklassige biometrische Lösung ... Snapdragon™ 835 mit X16 LTE auf dem ... 2. März) am Qualcomm-Stand in Halle 3, ... 835-Prozessor beinhaltet die Sicherheitsplattform Qualcomm Haven™ – ...
(Date:2/26/2017)... 25, 2017  Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, announces the ... "Too often, too many offenders return ... jails are trying to tackle this ongoing problem ... and family members. While significant steps are underway, Securus ...
Breaking Biology News(10 mins):